EP1189543A1 - Dispositif d'amygdalectomie sub-muqueuse par radiofrequence - Google Patents

Dispositif d'amygdalectomie sub-muqueuse par radiofrequence

Info

Publication number
EP1189543A1
EP1189543A1 EP00948513A EP00948513A EP1189543A1 EP 1189543 A1 EP1189543 A1 EP 1189543A1 EP 00948513 A EP00948513 A EP 00948513A EP 00948513 A EP00948513 A EP 00948513A EP 1189543 A1 EP1189543 A1 EP 1189543A1
Authority
EP
European Patent Office
Prior art keywords
energy delivery
delivery device
tonsil
distal end
electrode
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00948513A
Other languages
German (de)
English (en)
Inventor
Lionel Nelson
Stuart D. Edwards
Ashoor S. Yourgenlow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyrus Ent LLC
Original Assignee
Somnus Medical Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somnus Medical Technologies Inc filed Critical Somnus Medical Technologies Inc
Publication of EP1189543A1 publication Critical patent/EP1189543A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1485Probes or electrodes therefor having a short rigid shaft for accessing the inner body through natural openings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B18/1477Needle-like probes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B18/04Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating
    • A61B18/12Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
    • A61B18/14Probes or electrodes therefor
    • A61B2018/1405Electrodes having a specific shape
    • A61B2018/1425Needle

Definitions

  • This invention relates to an apparatus to treat tonsils and/or pharyngeal structures, and more particularly, to an apparatus that creates cell necrosis within the intratonsil lymphoid stroma, the pharyngeal or pterygoid fat pad while substantially preserving the underlying tonsil capsule, overlying mucosa and adjacent and/or underlying pterygoid muscle, vessels and nerves.
  • Tonsillectomy is a procedure indicated for recurrent infection of the tonsils and surrounding tissues and/or airway obstruction caused by the tonsils. It is one of the most frequently performed operations in the western world. Post-operatively, it is also one of the most painful due to the resultant exposure of unprotected oropharyngeal nerve and surrounding muscle tissue. The healing process is a slow taking between two to three weeks for the injured tissue to become overgrown with new epithelial/mucous membrane tissue. This period is typically characterized by considerable pain, dehydration and weight loss due to difficulty in swallowing as well as occasional hemorrhaging.
  • Tonsillectomies and adenotonsillectomies are some of the most commonly performed surgical procedures in the United States and elsewhere, with an estimated 340,000 procedures performed in the United States each year.
  • the major complication of tonsillectomy is post-operative hemorrhage.
  • electrocoagulation has been used more frequently to achieve hemostasis.
  • suction electrocoagulation for removal of tonsils is an effective method with minimal blood loss (e.g. blood vessels are electrocoagulated as they are encountered), the procedure has several important limitations.
  • First is the fact that coagulation causes trauma to surrounding and subjacent tissues 1 to 2 mm beyond the point of contact. This causes unwanted tissue necrosis and may lead to late post-operative bleeding.
  • suction electrocoagulation devices heretofore presented are not good dissecting instruments. Nonetheless, there is a tendency to use such electrocoagulation devices to cut through adherent tissue which leads to even greater tissue trauma.
  • the other option is to switch back and forth between using a suction electrocoagulation device and a dissecting instrument such as a Fischer "hockey-stick" style dissector. Such switching between instruments prolongs the surgery and the time the patient must remain under anesthetic, permits additional hemorrhaging during instrument changes, and decreases efficiency.
  • Laryngoscope used this technique in 265 patients. The study demonstrated its effectiveness and also negligible delayed post-operative bleeding.
  • the bipolar electrocoagulating forceps is designed principally for coagulation. If suction is needed, which is not uncommon, another instrument must be introduced into the operating field. To some degree, a bipolar coagulator may be used as a dissecting instrument; there are many instances where conventional dissection is more advantageous as dissection is not inherent in the bipolar coagulator's design.
  • an object of the invention is to provide an apparatus to treat tonsils.
  • the apparatus includes an elongated member with a longitudinal axis.
  • the elongated member being is configured to be position able and maneuverable in an oral cavity.
  • First and second energy delivery devices are positioned at a distal portion of the elongated member. Each of the first and second energy delivery devices is laterally offset from the longitudinal axis.
  • the tonsil treatment apparatus includes a template including a first tissue penetrating introducer with a first lumen.
  • a first energy delivery device is at least partially position able in the first lumen.
  • the first energy delivery device is advanceable from the first lumen into a tonsil intratonsil lymphoid stroma.
  • a method of reducing the size of the tonsil provides an elongated member coupled to a first energy delivery device with an energy delivery surface. At least a portion of the energy delivery surface is delivered into an interior of the tonsil. Cell necrosis is created in the tonsil intratonsil lymphoid stroma while preserving a tonsil fibrous capsule.
  • FIG. 1 is a lateral view of the oral cavity illustrating the anatomy of the oral cavity including the tonsil and pterygoid muscle and pharyngeal/pterygoid fat pad.
  • FIG. 2a is a lateral view of the oral cavity illustrating positioning of the tonsil treatment apparatus of the present invention in the oral cavity.
  • FIG. 2b is a perspective view illustrating positioning of the tonsil treatment apparatus and the creation of cell necrosis of the stroma of the tonsil.
  • FIG. 3 is a lateral view of the treatment apparatus shown in FIGS. 2a and 2b, illustrating the handpiece, elongated member, template and energy delivery device of one embodiment of the apparatus.
  • FIG. 4 is a straight-on perspective view of the distal end of the handpiece shown in FIG. 3 illustrating the configuration and connection of the elongated members to the handpiece.
  • FIG. 5 is closeup view of FIG. 4 illustrating one embodiment of the template and the spacing of the electrodes within the template.
  • FIG. 6 is an oblique side view of one embodiment of the invention further illustrating the spacing of the distal portion of the elongated member, template, tissue piercing stylets and electrode as well as the use of insulating material over portions of the electrode.
  • FIG. 7 is a frontal view illustrating the tissue interface surface of the template including lumens/stylet openings.
  • FIG. 8a illustrates a perspective view /schematic diagram of the cell necrosis apparatus of the present invention coupled to an energy source and a ground pad electrode and operation of the electrode in a monopolar mode.
  • FIG. 8b is a perspective view/schematic diagram illustrating the current flow for RF electrodes operating in a bipolar mode.
  • FIG. 9a is a lateral view of distal portion of the apparatus illustrating an embodiment of the apparatus of FIG. 1 that includes tissue piercing stylets.
  • FIG. 9b is an angled lateral view of FIG. 8b illustrating the use of tissue piercing stylets and blunt ball tip electrode to position the electrode in the intratonsil lymphoidstoma while avoiding the back capsule wall of the tonsil.
  • FIG. 9c is lateral view of illustrating the use of an atraurnatic/compressible coating on the electrode ball tip along with a force sensor positioned at the electrode tip to provide physician feedback.
  • FIG. 10 depicts a block diagram of the feed back control system that can be used with the apparatus as shown in FIGS. 2 and 3.
  • FIG 11 depicts a block diagram of an analog amplifier, analog multiplexer and microprocessor used with the feedback control system of Figure 10.
  • FIG 12 depicts a block diagram of the operations performed in the feedback control system depicted in Figure 10.
  • a cell necrosis apparatus 10 also called tonsil treatment apparatus 10 or submucosal tonsillectomy apparatus 10
  • tonsil treatment apparatus 10 or submucosal tonsillectomy apparatus
  • an ablation procedure shall be meant to include one or more of the following affects: thermal damage, tissue shrinkage, tissue scarring, remodeling, debulking and ablating tissue.
  • apparatus 10 can be configured to treat and ablate tissue within the pharyngeal fat pad, pterygoid fat pad or other pharyngeal structure.
  • Cell necrosis apparatus 10 can be positioned at a treatment site 13 to deploy one or more energy delivery devices 14, also called electrodes 14.
  • Each energy delivery device 14 may be a needle energy delivery device and each is introduced into an interior of the tonsil 11 through a surface 11' of the tonsil.
  • Ablation apparatus 10 may configured for atraumatic intubation with or without visualization, provide for the delivery of oxygen or anesthetics, and can be capable of suctioning blood or other secretions.
  • apparatus 10 is used to treat the tonsils 11. Specifically, apparatus 10 is used to ablate the intratonsil lymphoid stroma 11" while sparing or minimizing injury to the underlying tonsil capsule 11'" and overlying mucosa I T. Apparatus 10 is positioned transorally and electrode 14 is advanced through the tonsillar mucosa 11' under local anesthesia. An adequate temperature is attained (e.g. 70 to 100° C) at the treatment site 13 and/or surrounding tissue in order to sterilize any infected portions of the tonsil within or around treatment site 13.
  • An adequate temperature is attained (e.g. 70 to 100° C) at the treatment site 13 and/or surrounding tissue in order to sterilize any infected portions of the tonsil within or around treatment site 13.
  • apparatus 10 can be configured to treat and ablate selected portions of the pharyngeal fat pad or pterygoid fat pad while substantially preserving and preventing injury to overlying mucosa and underlying muscle and pharyngeal arteries, veins and nerves.
  • Various medical imaging methods known in the art including CT scan, ultrasound, endoscopy and fluoroscopy can used with this procedure to facilitate placement of apparatus 10 in the desired pharyngeal anatomy as well as provide the physician feedback on the ablation process.
  • treatment apparatus 10 includes an elongated member 12 with a longitudinal axis 10'.
  • elongated member 12 is coupled to a handpiece or shell 15.
  • a plurality of energy delivery devices 14 are positioned at a distal portion 16 of elongated member 12.
  • energy delivery device apparatus 10 is configured to create a selectable area of cell necrosis 13' at treatment site 13.
  • Elongated member 12 can be a catheter, hypotube, guidewire or handpiece, or a combination thereof that is configured to be both positionable and maneuverable in an oral cavity such as the throat including the pharynx and the larynx.
  • elongated member 12 can be fabricated from extrudable resilient polymers such as polyethylene, formable metals such as stainless steel and shape memory metals such as nitinol.
  • elongated member 12 can be a 0.035" nitinol wire which may or may not be coated with an insulating polymer material over all or part of its length.
  • Elongated member can have one or more lumens 12' configured for the advancement of guidewires, catheters, hypotubes, fiberoptic viewing devices and the like as well as providing ports for providing suction/aspiration, pressure, fluid delivery, and drug delivery.
  • elongated member 12 can be catheter or hypotube with an advanceable corewire 12" such as a 0.035" nitinol wire that is advanced through lumen 12' to reach a target tissue site 13.
  • handpiece 15 can be cylindrically shaped and fabricated from moldable plastics such as nylon, polystyrene, polycarbonate, acrylic, or a combination thereof using injection molding or other polymer processing methods known in the art.
  • handpiece 15 can be connected to the proximal end 16' of elongated member 12 using adhesive or solvent bonding, hot melt junction, shrink tubing or other plastic joining method known in the art.
  • handpiece 15 can include a slidable mechanism or actuator 15" which is mechanically coupled to elongated member 12 to laterally advance elongated member 12 within an oral cavity and/or deflect distal portions 16 of elongated member 12.
  • actuator 15" can comprise a ring that slides over handpiece 15 along a lateral slot within the handpiece.
  • handpiece 15 can include an electrical connector 15"' such as a lemo connector used to connect electrode 14 and or sensor 22 to monitoring device 23, control system 25 or a power source 26.
  • electrical connector 15"' such as a lemo connector used to connect electrode 14 and or sensor 22 to monitoring device 23, control system 25 or a power source 26.
  • one or more elongated members 12 can be coupled to handpiece 15.
  • At least a majority of energy delivery devices 14 are laterally offset from the longitudinal axis 10' by an angle 10". In one embodiment, energy delivery devices 14 are offset by approximately 90 degrees. In other embodiments, energy delivery devices are offset in the range of 0 to 90 degrees with specific embodiments of 15, 30, 45 and 60 degrees. The offset is preferred in order to more readily position energy delivery devices 14 at an exterior 1 1' of an oral anatomical structure such as tonsil 11.
  • embodiments of apparatus 10 can also include a template 17 which is positioned at the distal portion 16 of elongated member 12.
  • template 17 can be a pressure plate that is positioned on an exterior surface of the selected anatomical structure. Template 17 includes a tissue interface surface 18 (illustrated in FIG.
  • tissue interface surface 18 can be configured to be tissue piercing, with a pointed and/or needle shape tip 18' similar to a hypodermic needle.
  • Template 17 and also be made non-conductive to the transmission of electrical, thermal or other electromagnetic energy.
  • template 17 can be made out of moldable thermoset plastics or forged or machined metals such as stainless steel (304v) or tool steel.
  • template has two stylets 24 separated by 10 mm (at their center lines) configured to receive and guide two RF electrodes including needle electrodes. In this embodiment, each electrode can be coupled to a separate elongated member 12.
  • template 17 can have a flat lonzenged shape, while in other embodiments template 17 can be substantially oval, circular or rectangular in shape. Also in various embodiments, template 17 can be configured to have one or more lumens 24 or stylets 24 to hold/guide one or more electrodes 14 into a tonsil tissue site 13. Template 17 can be the size of a tonsil's face, while stylets 24 may be 4 mm hollow channels (or lumens 24) with needle sharp tips 24' which are capable of penetrating mucosal tissue and subjacent fibrous stroma or other tissue.
  • template 17 includes one or more electrode stylets 24 which extend from tissue interface surface 18.
  • Stylets 24 have tissue- piercing distal ends 24'.
  • the distal ends 14" of electrodes 14 are less tissue piercing than the distal ends 24' of stylets 24 but have geometries that are readily advanceable through tonsil tissue 11 including the intratonsil lymphoid stroma 11 " as well as pharyngeal structures such as the pharyngeal or pterygoid fat pad.
  • electrode tips 14" are sufficiently tissue piercing to be positioned in tonsil tissue 11 without the use of stylets 24.
  • energy delivery device 14 can be an RF electrode, a microwave antenna, ultrasound transducer, resistive heater or liquid thermal jet.
  • energy delivery device 14 is an RF electrode operated in either a bipolar or monopolar mode and energy source 26 is an RF source 26.
  • a monopolar mode of delivering RF energy a single electrode 14 is used in combination with an indifferent electrode patch 19 electrically coupled to power source 26 that is applied to the body to form the other contact and complete an electrical circuit with power source 26.
  • Bipolar operation is possible when two or more electrodes 14 are used. Current flows from portions of a first electrode 14 to a second electrode 14'.
  • multiple RF electrodes 14 are included.
  • RF electrodes 14 are preferably needle electrodes with diameters in the range of 0.005 to 0.5" with specific embodiments of 0.01, 0.05 and 0.1 inches; and including needle gauges of 10-22 with specific embodiments of 12, 18 and 22 gauge. RF electrodes 14 are tissue piercing and advanceable through the selected anatomical structure.
  • an insulator 20 can be positioned at the exterior of one or all of RF electrodes 14. Insulator 20 can be a moveable sleeve, adjustable in length and in a surrounding relationship to an exterior surface of energy delivery device 14. Insulator 20 serves as a barrier to thermal or RF energy flow. Insulator 20 can be in the form of a sleeve that may be adjustably positioned at the exterior of energy delivery device 14. In various embodiments, insulator 20 can be made of a polyester shrink wrap (0.002 inch thickness), or a polyamide, polyimide or Teflon® material.
  • one or more sensors 22 can be included and positioned at a distal end 14"of electrode 14, at a distal end of insulator 20, as well as at other positions of cell necrosis apparatus 10.
  • Sensor 22 is of conventional design, including but not limited to thermistors, thermocouples, resistive wires, and the like.
  • a suitable sensor 22 is a T type thermocouple with copper constantene, J type, E type, K type, fiber optics, resistive wires, thermocouple IR detectors, and the like.
  • Each electrode 14 can experience a steep temperature rise or gradient as current moves outward through the electrode. This temperature rise causes tissue that is immediately adjacent to electrode 14 to reach temperatures of 100° C or more while tissue only 5 to 10 mm away may be at or near body temperature. Because of this temperature gradient, it is often necessary to place and remove electrode 14 several times from the treatment site 13 or use a plurality of electrodes 14 to create a cell necrosis zone 13' of the desired volume. Because of significant heating of tissue immediately proximal of electrode 14, desiccation of tissue adjacent to electrode 14 may result. When the fluid within the tissue is desiccated, minimal or no electrical current flows through the tissue and heating ceases. This problem can be alleviated by using a lower rate of heating which requires extended treatment periods. Referring now to FIG.
  • cooling device or means 33' can be a cooling fluid (e.g. chilled saline), a cryogenic fluid (e.g a refrigerant) or a peltier effect device.
  • cooling fluid 33 can be coupled to a fluid delivery device 33' (e.g. a peristaltic or other pump) to facilitate delivery of cooling fluid 33 to electrode 14 and/or tissue site 13.
  • Fluid delivery device 33' may have an integral fluid reservoir 33".
  • electrodes 14 may have non-conducting blunt ball tips 14" (also called atraumatic tip 14" or blunt tip 14" or tip 14") which are deployed through stylets 24 into the tonsil lymphoid stroma.
  • atraumatic tip 14" can have other atraumatic/non piercing geometric shapes including but not limited to cylindrical, circular, oval, spherical and hemispherical; one more of which may have a concave or convex surface 14'".
  • blunt tip 14" can have a cross sectional diameter 27 less than a cross sectional diameter 27' of an elongated proximal portion 29 of electrode 14.
  • tip 14" can be coupled to a force/pressure sensor 22' coupled to a monitoring device 23 to provide the physician feedback on the amount of force/pressure being applied by tip 14" against adjacent tissue and assist him or her in reducing the likelihood of penetration of the back capsule wall.
  • force/pressure sensor 22' can include a strain gauge, or solid state based (e.g. silicon) pressure/force sensor known in the art.
  • electrodes 14 can be positioned at treatment site 13 in the tonsil 11 or other oral structure without the use of template 17. This can be achieved using electrodes 14 that are either tissue piercing or have fully or partially blunt tip 14". In related embodiments, placement of electrodes 14 without template 17 can be facilitated with the use of sensor 22 including a pressure sensor 22' positioned at tip 14". Placement of electrode 14 can also be facilitated by the use of an endoscopic or fiberoptic viewing device or a medical imaging modality known in the art such as ultrasound, fluoroscopy, MRI or CT scans.
  • the blunt ball tips 14" of electrodes 14 can be configured to be atraumatic and/or less likely to puncture tissue through the use of atraumatic soft/compressible coatings 21 such as silicone or other medical elastomers known in the art, as well as foam polymer material known in the art. Coating 21 can be configured to compress to absorb some of the force
  • coating 21 is configured to have a compressive modulus 21' less than that of capsule wall of the tonsil.
  • coating 21 can be configured to be electrically and/or thermally insulative and can be the same as or otherwise integral with insulator 20.
  • cell necrosis apparatus 10 is coupled to an open or closed loop feedback system 25.
  • open or closed loop feedback system 25 couples sensor 346 to energy source 392.
  • energy delivery device 314 is one or more RF electrodes 314.
  • the temperature of the tissue, or of RF electrode 314 is monitored, and the output power of energy source 392 adjusted accordingly. Additionally, the level of disinfection in the oral cavity can be monitored.
  • the physician can, if desired, override the closed or open loop system.
  • a microprocessor can be included and incorporated in the closed or open loop system to switch power on and off, as well as modulate the power.
  • the closed loop system utilizes a microprocessor 394 to serve as a controller, monitor the temperature, adjust the RF power, analyze at the result, refeed the result, and then modulate the power.
  • a tissue adjacent to RF electrode 314 can be maintained at a desired temperature for a selected period of time without impeding out.
  • Each RF electrode 314 is connected to resources which generate an independent output. The output maintains a selected energy at RF electrode 314 for a selected length of time.
  • Current delivered through RF electrode 314 is measured by current sensor 396.
  • Voltage is measured by voltage sensor 398. Impedance and power are then calculated at power and impedance calculation device 400. These values can then be displayed at user interface and display 402.
  • Signals representative of power and impedance values are received by a controller 404.
  • a control signal is generated by controller 404 that is proportional to the difference between an actual measured value, and a desired value.
  • the control signal is used by power circuits 406 to adjust the power output in an appropriate amount in order to maintain the desired power delivered at respective RF electrodes 314.
  • temperatures detected at sensor 346 provide feedback for maintaining a selected power. Temperature at sensor 346 is used as a safety means to interrupt the delivery of energy when maximum pre-set temperatures are exceeded.
  • the actual temperatures are measured at temperature measurement device 408, and the temperatures are displayed at user interface and display 402.
  • a control signal is generated by controller 404 that is proportional to the difference between an actual measured temperature and a desired temperature.
  • the control signal is used by power circuits 406 to adjust the power output in an appropriate amount in order to maintain the desired temperature delivered at the sensor 346.
  • a multiplexer can be included to measure current, voltage and temperature, at the sensor 346, and energy can be delivered to RF electrode 314 in monopolar or bipolar fashion.
  • Controller 404 can be a digital or analog controller, or a computer with software. When controller 404 is a computer it can include a CPU coupled through a system bus. On this system can be a keyboard, a disk drive, or other non-volatile memory systems, a display, and other peripherals, as are known in the art. Also coupled to the bus is a program memory and a data memory.
  • User interface and display 402 includes operator controls and a display.
  • Controller 404 can be coupled to imaging systems, including but not limited to ultrasound, CT scanners, X-ray, MRI, mammographic X-ray and the like. Further, direct visualization and tactile imaging can be utilized.
  • the output of current sensor 396 and voltage sensor 398 is used by controller 404 to maintain a selected power level at RF electrode 314.
  • the amount of RF energy delivered controls the amount of power.
  • a profile of power delivered can be incorporated in controller 404 and a preset amount of energy to be delivered may also be profiled.
  • Circuitry, software and feedback to controller 404 result in process control, and the maintenance of the selected power setting that is independent of changes in voltage or current, and used to change, (i) the selected power setting, (ii) the duty cycle (on-off time), (iii) bipolar or monopolar energy delivery and (iv) fluid delivery, including flow rate and pressure.
  • process variables are controlled and varied, while maintaining the desired delivery of power independent of changes in voltage or current, based on temperatures monitored at sensor 346.
  • Analog amplifier 410 can be a conventional differential amplifier circuit for use with sensor 346.
  • the output of analog amplifier 410 is sequentially connected by an analog multiplexer 412 to the input of A/D converter 414.
  • the output of analog amplifier 410 is a voltage which represents the respective sensed temperatures.
  • Digitized amplifier output voltages are supplied by A/D converter 414 to microprocessor 394.
  • Microprocessor 394 may be a type 68HCII available from Motorola. However, it will be appreciated that any suitable microprocessor or general purpose digital or analog computer can be used to calculate impedance or temperature.
  • Microprocessor 394 sequentially receives and stores digital representations of impedance and temperature. Each digital value received by microprocessor 394 corresponds to different temperatures and impedances. Calculated power and impedance values can be indicated on user interface and display 402. Alternatively, or in addition to the numerical indication of power or impedance, calculated impedance and power values can be compared by microprocessor 394 with power and impedance limits. When the values exceed predetermined power or impedance values, a warning can be given on user interface and display 402, and additionally, the delivery of RF energy can be reduced, modified or interrupted. A control signal from microprocessor 394 can modify the power level supplied by energy source 392. FIG.
  • FIG. 12 illustrates a block diagram of a temperature/impedance feedback system that can be used to control energy delivery and/or fluid flow rate to electrode 314 and/or a tissue site 416 to regulate the temperature of either or both.
  • Energy is delivered to RF electrode 314 by energy source 392, and applied to tissue site 416.
  • a monitor 420 ascertains tissue impedance, based on the energy delivered to tissue, and compares the measured impedance value to a set value. If the measured impedance exceeds the set value, a disabling signal 422 is transmitted to energy source 392, ceasing further delivery of energy to electrode 314. If measured impedance is within acceptable limits, energy continues to be applied to the tissue.
  • sensor 346 measures the temperature of tissue and/or electrode 314.
  • a comparator 424 receives a signal representative of the measured temperature and compares this value to a pre-set signal representative of the desired temperature. Comparator 424 sends a signal to a flow regulator 418 representing a need for a higher temperature control fluid flow rate, if the tissue temperature is too high, or to maintain the flow rate if the temperature has not exceeded the desired temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plasma & Fusion (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgical Instruments (AREA)

Abstract

Cette invention concerne un appareil de nécrose cellulaire constitué par un élément allongé avec axe longitudinal. Cet élément est conçu de manière à pouvoir être positionné et manipulé dans une cavité buccale. Un premier et un second dispositifs d'apport d'énergie sont implantés dans la partie distale de l'élément allongé. Chacun des premier et second dispositifs d'apport d'énergie est déporté latéralement par rapport à l'axe longitudinal. Selon un autre mode de réalisation, l'appareil comprend un gabarit avec un dispositif conçu pour pénétrer dans les tissus et une lumière. Le dispositif d'apport d'énergie est conçu pour avancer de la première lumière dans un stroma lymphoïde sus-amygdalien de l'amygdale.
EP00948513A 1999-06-18 2000-06-16 Dispositif d'amygdalectomie sub-muqueuse par radiofrequence Withdrawn EP1189543A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33602199A 1999-06-18 1999-06-18
US336021 1999-06-18
PCT/US2000/016800 WO2000078240A1 (fr) 1999-06-18 2000-06-16 Dispositif d'amygdalectomie sub-muqueuse par radiofrequence

Publications (1)

Publication Number Publication Date
EP1189543A1 true EP1189543A1 (fr) 2002-03-27

Family

ID=23314225

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00948513A Withdrawn EP1189543A1 (fr) 1999-06-18 2000-06-16 Dispositif d'amygdalectomie sub-muqueuse par radiofrequence

Country Status (5)

Country Link
EP (1) EP1189543A1 (fr)
JP (1) JP2003502105A (fr)
AU (1) AU768830B2 (fr)
CA (1) CA2371899A1 (fr)
WO (1) WO2000078240A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534235B2 (en) 2019-04-04 2022-12-27 Acclarent, Inc. Needle instrument for posterior nasal neurectomy ablation
US11786296B2 (en) 2019-02-15 2023-10-17 Accularent, Inc. Instrument for endoscopic posterior nasal nerve ablation
US12011213B2 (en) 2019-03-29 2024-06-18 Acclarent, Inc. System and method for treating epistaxis

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6409722B1 (en) 1998-07-07 2002-06-25 Medtronic, Inc. Apparatus and method for creating, maintaining, and controlling a virtual electrode used for the ablation of tissue
EP1263341B1 (fr) 2000-03-06 2008-06-11 Salient Surgical Technologies, Inc. Systeme et regulateur de distribution de fluide pour dispositifs d'electrochirurgie
US7811282B2 (en) 2000-03-06 2010-10-12 Salient Surgical Technologies, Inc. Fluid-assisted electrosurgical devices, electrosurgical unit with pump and methods of use thereof
US6689131B2 (en) 2001-03-08 2004-02-10 Tissuelink Medical, Inc. Electrosurgical device having a tissue reduction sensor
US6558385B1 (en) 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US8048070B2 (en) 2000-03-06 2011-11-01 Salient Surgical Technologies, Inc. Fluid-assisted medical devices, systems and methods
EP2275050A1 (fr) 2001-09-05 2011-01-19 Salient Surgical Technologies, Inc. Dispositifs, procédés et systèmes chirurgicaux assistés par un fluide
EP1572020A4 (fr) 2002-10-29 2006-05-03 Tissuelink Medical Inc Ciseaux electrochirurgicaux utilisant un fluide et leurs procedes d'utilisation
WO2004080278A2 (fr) 2003-03-06 2004-09-23 Tissuelink Medical, Inc. Procedes, systemes et dispositifs medicaux assistes d'un fluide
JP4076019B2 (ja) * 2003-03-11 2008-04-16 株式会社日本エム・ディ・エム 生体組織処理用電極棒
US7727232B1 (en) 2004-02-04 2010-06-01 Salient Surgical Technologies, Inc. Fluid-assisted medical devices and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514131A (en) * 1992-08-12 1996-05-07 Stuart D. Edwards Method for the ablation treatment of the uvula
US5707349A (en) * 1994-05-09 1998-01-13 Somnus Medical Technologies, Inc. Method for treatment of air way obstructions
US5843021A (en) * 1994-05-09 1998-12-01 Somnus Medical Technologies, Inc. Cell necrosis apparatus
US5743904A (en) * 1996-05-06 1998-04-28 Somnus Medical Technologies, Inc. Precision placement of ablation apparatus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0078240A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11786296B2 (en) 2019-02-15 2023-10-17 Accularent, Inc. Instrument for endoscopic posterior nasal nerve ablation
US12011213B2 (en) 2019-03-29 2024-06-18 Acclarent, Inc. System and method for treating epistaxis
US11534235B2 (en) 2019-04-04 2022-12-27 Acclarent, Inc. Needle instrument for posterior nasal neurectomy ablation

Also Published As

Publication number Publication date
WO2000078240A1 (fr) 2000-12-28
JP2003502105A (ja) 2003-01-21
CA2371899A1 (fr) 2000-12-28
AU6199300A (en) 2001-01-09
AU768830B2 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
US6682501B1 (en) Submucosal tonsillectomy apparatus and method
JP2647557B2 (ja) Bph切除方法及び装置
AU718288B2 (en) Apparatus for cosmetically remodeling a body structure
US8790339B2 (en) Apparatus to detect and treat aberrant myoelectric activity
US5820580A (en) Method for ablating interior sections of the tongue
US8870862B2 (en) Method to treat gastric reflux via the detection and ablation of gastro-esophageal nerves and receptors
US6126657A (en) Apparatus for treatment of air way obstructions
US6006755A (en) Method to detect and treat aberrant myoelectric activity
US5879349A (en) Apparatus for treatment of air way obstructions
US6056744A (en) Sphincter treatment apparatus
US20020107512A1 (en) Sphincter treatment apparatus
US20020103483A1 (en) Apparatus to treat esophageal sphincters
WO1999042044A1 (fr) Appareil electrochirurgical de traitement des sphincters
EP0901398A1 (fr) Procede et appareil pour pratiquer de la chirurgie esthetique sur une structure corporelle
KR20000010723A (ko) 기도 장애물 치료 방법 및 장치
AU768830B2 (en) Submucosal radiofrequency tonsils ablation device
AU725853B2 (en) Apparatus for cosmetically remodeling a body structure
WO1997006741A2 (fr) Appareil pour le remodelage esthetique d'un organe d'un corps humain
WO1997043973A1 (fr) Procede pour l'ablation de sections interieures de la langue
WO1997043969A1 (fr) Appareil de remodelage esthetique d'une structure corporelle
AU2872299A (en) Apparatus to detect and electrosurgically treat aberrant myoelectric activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20030822

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GYRUS ENT, L.L.C.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060103